However, recent studies have shown that many types of cancer cells, including pancreatic ductal adenocarcinoma cells, are resistant to the apoptotic effects of TRAIL [11–13], suggesting that treatment with TRAIL alone may not be sufficient for treating pancreatic cancer. This evidence concerns the gene TNFSF10 and pancreatic ductal adenocarcinoma.